… Dual IGF-1R/ErbB3 blockade inhibits growth factor–induced … that dual blocking of IGF-1R
and ErbB3 can effectively inhibit … bispecific antibody istiratumab to inhibit AKT activation in …

… , an IGF-1R- and ErbB3-bispecific antibody, can enhance the … activity of nab-paclitaxel/gemcitabine,
through inhibition of AKT phosphorylation and promotion of IGF-1R and ErbB3 …

… the effects of dual IGF-1R/ErbB3 inhibition on ovarian cancer cell … , whereas dual blocking
of IGF-1R and ErbB3 enhances the … nab-paclitaxel plus gemcitabine versus nab-paclitaxel and …

… data suggest that dual blockade of the IGF-1 and HER3 pathways has superior activity to
IGF… We tested whether istiratumab, an IGF-1R and ErbB3 bi-specific antibody, can enhance the …

… Mechanistically, activated IGF-1R promotes an array of … binds to and co-inhibits IGF-1R and
HER3, has released its results … of glucose metabolism by this dual IGF-1R/InsR TKI, patients …

… , enhances drug sensitivity by blocking inhibition of AKT phosphorylation and promoting
degradation of IGF-1R … In an RCT, ganitumab, an IGF-1R antibody, was added to gemcitabine, …

… IGF-1R and ErbB3 promotes ovarian cancer cell proliferation and pro-survival signaling
activation, whereas the dual blocking of IGF-1R and ErbB3 enhances … to the gemcitabine and (…

… inhibition [45] in pancreatic cancer. Of note, IGF1R and ErbB3-bispecific antibodies enhance
the … activity was determined using Secrete-Pair Dual Luminescence Assay Kit accordingly. …

… of IGF-1R in pancreatic cancer cells, with subsequent increase of … kinase inhibitors of IGF-1R.
In preclinical studies, the … mg/m2 of gemcitabine plus 125 mg/m2 of nabpaclitaxel once a …

… adaptive mechanism that promotes resistance and tumorigenicity … IGF-1R inhibition, thereby
limiting sustained inhibition of downstream signaling and contributing to resistance to IGF-1R…